Detalhe da pesquisa
1.
Susceptibility Testing of Medically Important Parasites.
Clin Microbiol Rev
; 30(3): 647-669, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28446445
2.
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.
Antimicrob Agents Chemother
; 62(9)2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29941635
3.
Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents.
J Antimicrob Chemother
; 72(11): 3051-3058, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961865
4.
In vitro activity of anti-malarial ozonides against an artemisinin-resistant isolate.
Malar J
; 16(1): 45, 2017 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28122617
5.
Functional dissection of intersubunit interactions in the EspR virulence regulator of Mycobacterium tuberculosis.
J Bacteriol
; 196(10): 1889-900, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24633871
6.
Virulence regulator EspR of Mycobacterium tuberculosis is a nucleoid-associated protein.
PLoS Pathog
; 8(3): e1002621, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22479184
7.
Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps.
ACS Infect Dis
; 10(5): 1458-1482, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661541
8.
High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae.
EBioMedicine
; 102: 105073, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38520916
9.
Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".
Antimicrob Agents Chemother
; 62(11)2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355750
10.
Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections.
Nat Rev Drug Discov
; 22(12): 957-975, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37833553
11.
Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline.
Microbiol Spectr
; 11(3): e0523622, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37158739
12.
Atypical DNA recognition mechanism used by the EspR virulence regulator of Mycobacterium tuberculosis.
Mol Microbiol
; 82(1): 251-64, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21883526
13.
Cation ATPase (ATP4) Orthologue Replacement in the Malaria Parasite Plasmodium knowlesi Reveals Species-Specific Responses to ATP4-Targeting Drugs.
mBio
; 13(5): e0117822, 2022 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36190127
14.
Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials.
Trends Parasitol
; 37(8): 709-721, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34001441
15.
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance.
Sci Transl Med
; 13(603)2021 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34290058
16.
Plasmodium knowlesi exhibits distinct in vitro drug susceptibility profiles from those of Plasmodium falciparum.
Int J Parasitol Drugs Drug Resist
; 9: 93-99, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30831468
17.
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
Nat Med
; 23(8): 917-928, 2017 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28777791
18.
A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
ACS Infect Dis
; 2(12): 945-957, 2016 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27641613